Etoricoxib in Thailand

Etoricoxib is an oral prescription anti-inflammatory from the coxib family. It is used to control the pain and swelling of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, short-term musculoskeletal pain and acute gout attacks.

It works by targeting inflammation at its source. When tissue is injured or arthritic, it switches on an enzyme called COX-2, which produces prostaglandins, the chemical messengers behind pain, heat and swelling. Etoricoxib selectively blocks COX-2 while largely leaving COX-1 alone. Because COX-1 is the enzyme that keeps the stomach lining protected, sparing it means fewer ulcers and bleeds than with older, non-selective NSAIDs.

That selectivity is also its trade-off. The same COX-2 blockade that eases pain shifts the balance of signals in blood vessels, which is why coxibs as a class can raise blood pressure and cardiovascular risk. Etoricoxib is one option among several, and whether it suits you depends on your pain, your heart and blood-pressure profile, your kidneys and your stomach history. That is what the doctor's assessment is for.

For pain and inflammation, etoricoxib is well established. In arthritis trials it relieves osteoarthritis, rheumatoid arthritis and ankylosing spondylitis symptoms as effectively as traditional NSAIDs, and for acute gout, etoricoxib 120 mg once daily matched indomethacin, the long-standing standard, in randomised trials while causing less gastrointestinal upset.

The safety picture is where honesty matters. In the MEDAL programme, the largest coxib outcomes study with 34,701 patients, etoricoxib caused fewer upper-gastrointestinal events than diclofenac, but the rate of thrombotic heart events was similar, and more patients stopped it because of raised blood pressure. That balance, real GI benefit against a genuine cardiovascular cost, is why it is prescription-controlled and why the US FDA declined to approve it.

What that means in practice: for a short gout course or occasional flare, the exposure is brief and the stomach advantage is real. For daily long-term arthritis use the calculation changes, which is why European regulators reviewed the whole coxib class in 2005, why the label keeps chronic osteoarthritis dosing at the lowest strengths (30–60 mg) and why blood pressure must be controlled before starting. It is an effective option for the right patient, not a default painkiller.